Site Search



David Teplow, Ph.D.

Email Address:
dteplow@ucla.edu

Laboratory Address:
635 Charles E. Young Drive South
Los Angeles, CA 90095

Office Address:
NRB 445


Fax Number:
310-206-1700
Work Phone Number:
310-206-2030



Login to the Faculty Database

Department / Division Affiliations
Director, Biopolymer Laboratory (A protein/peptide chemistry core facility)
Professor, Neurology, Brain Research Institute, Molecular Biology Institute
Professor in Residence, Neuroscience Graduate Program
Member, ACCESS Program: MBI IDP
ACCESS Affinity - Molecular Basis of Disease

Research Interest:

Understanding Alzheimer's disease and other diseases of aging

The Teplow laboratory seeks to understand and treat diseases associated with the aging process. These include Alzheimer's disease (AD), Parkinson's disease, Huntington's disease, and Lou Gehrig's disease. The laboratory has special expertise in AD, the most common cause of late-life dementia. A key cause of AD is thought to be a protein called the amyloid beta-protein (Abeta). This protein deposits in the brain to form what are called "amyloid plaques." Our group has worked to understand how these plaques form and to use this knowledge to design drugs to prevent or treat the disease. Our studies have revealed that Abeta shares properties with other proteins linked to human diseases of aging, therefore the work done on AD is likely to advance efforts to understand and treat these disorders.

Bio:

David Teplow received B.A. degrees in Biochemistry (1974) and in Bacteriology and Immunology (1975) at the University of California at Berkeley. He did graduate work in Tumor and Molecular Immunology at the University of Washington, where he received his M.S. (1977) and Ph.D. (1981) degrees. His graduate work, which involved protein chemical studies of cell surface receptors, led him to Caltech in Pasadena, where he worked first as a postdoctoral fellow and then as a junior faculty member to develop highly sensitive methods for protein primary structure analysis and to apply these new methods to the study of proteins in the nervous system. From 1991 through 2004, Dr. Teplow was a faculty member in the Departments of Neurology at Brigham and Women's Hospital and Harvard Medical School, where he established a research program to understand the structural biology of the amyloid β-protein (Aβ) and its contribution to the pathogenesis of Alzheimer's disease (AD). Dr. Teplow joined the faculty at UCLA in 2005, where he currently is a Professor in Residence in the Department of Neurology, a member of the Molecular Biology Institute and the Brain Research Institute, and Director of the Biopolymer Laboratory at UCLA. Dr. Teplow is a leader in the areas of the structural biology of amyloid proteins and the biophysics of amyloid assembly. The Teplow laboratory seeks to understand and treat neurodegenerative disorders linked to pathologic protein folding. In AD, Aβ self-associates to form a variety of oligomeric and polymeric structures with potent neurotoxic activities. Aβ oligomers have been found in vivo in AD patients and may be the proximate neurotoxins in the disease. To understand how the nascent Aβ monomer folds and assembles into neurotoxic forms, Dr. Teplow has employed an interdisciplinary strategy comprising in vivo, in vitro, in vacuo, and in silico approaches. The long-term goal is to discover the key factors controlling production of neurotoxic assemblies and then to target these factors in strategies for drug development. Dr. Teplow has published ~140 peer-reviewed articles, including ~100 original articles and ~40 reviews, book chapters, and commentaries. Dr. Teplow was a founding editorial board member of the Journal of Molecular Neuroscience and currently sits on the editorial boards of The Journal of Biological Chemistry, Amyloid: The Journal of Protein Folding Disorders, Current Chemical Biology, and The Yemeni Journal of Science.

Publications:

Roychaudhuri R, Yang M, Hoshi MM, Teplow DB Amyloid β-protein assembly. J Biol Chem, 284:4749–4753 2009; .
Maji Samir K, Ogorzalek Loo Rachel R, Inayathullah Mohammed, Spring Sean M, Vollers Sabrina S, Condron Margaret M, Bitan Gal, Loo Joseph A, Teplow David B Amino Acid Position-specific Contributions to Amyloid {beta}-Protein Oligomerization.. The Journal of biological chemistry. 2009; 284(35): 23580-91.
Yang Mingfeng, Teplow David B Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences.. Journal of molecular biology. 2008; 384(2): 450-64.
Ono Kenjiro, Condron Margaret M, Ho Lap, Wang Jun, Zhao Wei, Pasinetti Giulio M, Teplow David B Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity.. The Journal of biological chemistry. 2008; 283(47): 32176-87.
Yamin Ghiam, Ono Kenjiro, Inayathullah Mohammed, Teplow David B Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.. Current pharmaceutical design. 2008; 14(30): 3231-46.
Grant Marianne A, Lazo Noel D, Lomakin Aleksey, Condron Margaret M, Arai Hiromi, Yamin Ghiam, Rigby Alan C, Teplow David B Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus.. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(42): 16522-7.